NCT04812262 - A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD | Biotech Hunter

Enrollment

255

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

December 20, 2022

Study Completion Date

February 14, 2023

Conditions

Overweight and ObesityType2 DiabetesNAFLD

Interventions

DRUG

DD01

The active of DD01 is a synthetic peptide, administered in a 1mL volume for injection.

DRUG

Placebo

Placebo drug of DD01, administered in a 1mL volume for injection

Trial Locations (4)

Combined Research Orlando, Orlando

Southwest General Healthcare Center, Fort Myers

Prosciento, Chula Vista

FDI Clinical Research, San Juan